Your browser doesn't support javascript.
loading
Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer.
Nalio Ramos, Rodrigo; Missolo-Koussou, Yoann; Gerber-Ferder, Yohan; Bromley, Christian P; Bugatti, Mattia; Núñez, Nicolas Gonzalo; Tosello Boari, Jimena; Richer, Wilfrid; Menger, Laurie; Denizeau, Jordan; Sedlik, Christine; Caudana, Pamela; Kotsias, Fiorella; Niborski, Leticia L; Viel, Sophie; Bohec, Mylène; Lameiras, Sonia; Baulande, Sylvain; Lesage, Laëtitia; Nicolas, André; Meseure, Didier; Vincent-Salomon, Anne; Reyal, Fabien; Dutertre, Charles-Antoine; Ginhoux, Florent; Vimeux, Lene; Donnadieu, Emmanuel; Buttard, Bénédicte; Galon, Jérôme; Zelenay, Santiago; Vermi, William; Guermonprez, Pierre; Piaggio, Eliane; Helft, Julie.
Afiliación
  • Nalio Ramos R; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Missolo-Koussou Y; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Gerber-Ferder Y; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Bromley CP; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK.
  • Bugatti M; Department of Pathology, University of Brescia, Brescia 25123, Italy.
  • Núñez NG; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Tosello Boari J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Richer W; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Menger L; PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France.
  • Denizeau J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Sedlik C; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Caudana P; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Kotsias F; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Niborski LL; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Viel S; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Bohec M; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.
  • Lameiras S; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.
  • Baulande S; PSL University, Institut Curie Research Center, Institut Curie Genomics of Excellence Platform, 75005 Paris, France.
  • Lesage L; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.
  • Nicolas A; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.
  • Meseure D; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.
  • Vincent-Salomon A; PSL University, Institut Curie Hospital, Department of Pathology, 75005 Paris, France.
  • Reyal F; PSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France.
  • Dutertre CA; Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France.
  • Ginhoux F; Université Paris-Saclay, Institut Gustave Roussy, INSERM U1015, Villejuif, France; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore.
  • Vimeux L; University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France.
  • Donnadieu E; University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, 75014 Paris, France.
  • Buttard B; INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France.
  • Galon J; INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers, Laboratory of Integrative Cancer Immunology, Paris, France.
  • Zelenay S; Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Manchester, UK.
  • Vermi W; PSL University, Institut Curie Research Center, INSERM U932, 75005 Paris, France; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Guermonprez P; Université de Paris, Centre for Inflammation Research, CNRS ERL8252, INSERM1149, Paris, France.
  • Piaggio E; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France.
  • Helft J; PSL University, Institut Curie Research Center, INSERM U932 & SiRIC, Translational Immunotherapy Team, 75005 Paris, France. Electronic address: julie.helft@inserm.fr.
Cell ; 185(7): 1189-1207.e25, 2022 03 31.
Article en En | MEDLINE | ID: mdl-35325594
Macrophage infiltration is a hallmark of solid cancers, and overall macrophage infiltration correlates with lower patient survival and resistance to therapy. Tumor-associated macrophages, however, are phenotypically and functionally heterogeneous. Specific subsets of tumor-associated macrophage might be endowed with distinct roles on cancer progression and antitumor immunity. Here, we identify a discrete population of FOLR2+ tissue-resident macrophages in healthy mammary gland and breast cancer primary tumors. FOLR2+ macrophages localize in perivascular areas in the tumor stroma, where they interact with CD8+ T cells. FOLR2+ macrophages efficiently prime effector CD8+ T cells ex vivo. The density of FOLR2+ macrophages in tumors positively correlates with better patient survival. This study highlights specific roles for tumor-associated macrophage subsets and paves the way for subset-targeted therapeutic interventions in macrophages-based cancer therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Macrófagos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Macrófagos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos